Table 1.

Antibody-based therapeutics in Phase 3 studies as treatments for cancer indications

Sponsoring company	International non-proprietary name	Target; description	Indication of Phase 3 study
Active Biotech Research	Naptumomab estafenatox	5T4; Fab conjugated to staph. enterotoxin A	Advanced renal cell carcinoma*
Amgen	AMG 386	Angiopoietin-1 and -2; target-binding peptide fused to Fc of human IgG1	Epithelial ovarian, primary peritoneal or fallopian tube cancers
Wilex AG	Girentuximab	Carbonic anhydrase ix; IgG1	Non-metastatic renal cell carcinoma
Abbott/Bristol-Myers Squibb	Elotuzumab	CD2; IgG1	Multiple myeloma
TenX Biopharma/Genmab	Zanolimumab	CD4; IgG1	Mycosis fungoides or Sezary syndrome
Glycart/Genentech/Biogen Idec	Obinutuzumab	CD20; glyco-engineered IgG1	Chronic lymphocytic leukemia; non-Hodgkin lymphoma; advanced diffuse large B-cell lymphoma
Pfizer	Inotuzumab ozogamicin	CD22; IgG1 conjugated to calicheamicin	Relapsed/refractory aggressive non-Hodgkin lymphoma
ImClone	Necitumumab	EGFR; IgG1	Non-small cell lung cancer
Morphotek	Farletuzumab	Folate receptor α IgG1	Ovarian cancer; adenocarcinoma of the lung
Genentech	Trastuzumab emtansine	HER2; IgG1 conjugated to DM1	Locally advanced or metastatic breast cancer
Genentech	Pertuzumab	HER2; IgG1	Metastatic breast cancer
Imclone Systems/Eli Lilly	Ramucirumab	VEGFR2; IgG1	Metastatic gastric or gastroesophageal junction adenocarcinoma; breast cancer; non-small cell lung cancer; hepatocellular carcinoma; colorectal cancer

Note: Information current as of October 31, 2011. *Study NCT00420888 listed as Phase 2/3 on clinicaltrials.gov web site. Abbreviations: CD, cluster of differentiation; EGFR, epidermal growth factor receptor; Fab, antigen-binding fragment; HER2, human epidermal growth factor receptor; VEGFR2, vascular endothelial cell growth factor receptor 2. International non-proprietary naming convention: -umab, human; -zumab, humanized; -ximab, chimeric; -momab, murine.